Literature DB >> 4783160

Methotrexate in liver and bile after intravenous dosage in man.

P J Creaven, H H Hansen, D A Alford, L M Allen.   

Abstract

Measurements of methotrexate have been made in the liver and plasma of 4 patients and in the bile and plasma of 1 patient receiving [(3)H]methotrexate. Projections from a theoretical model of concentration of methotrexate in liver are confirmed but projections of biliary excretion are not.

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4783160      PMCID： PMC2008933          DOI： 10.1038/bjc.1973.190

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  6 in total

1.  Inhibition of dihydrofolic reductase by aminopterin and amethopterin.

Authors:  M J OSBORN; M FREEMAN; F M HUENNEKENS
Journal:  Proc Soc Exp Biol Med       Date:  1958-02

2.  The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man.

Authors:  E S Henderson; R H Adamson; V T Oliverio
Journal:  Cancer Res       Date:  1965-08       Impact factor: 12.701

3.  Transport and binding of methotrexate in vivo.

Authors:  R L Dedrick; D S Zaharko; R J Lutz
Journal:  J Pharm Sci       Date:  1973-06       Impact factor: 3.534

4.  Methotrexate pharmacokinetics.

Authors:  K B Bischoff; R L Dedrick; D S Zaharko; J A Longstreth
Journal:  J Pharm Sci       Date:  1971-08       Impact factor: 3.534

5.  Preliminary model for methotrexate pharmacokinetics.

Authors:  K B Bischoff; R L Dedrick; D S Zaharko
Journal:  J Pharm Sci       Date:  1970-02       Impact factor: 3.534

6.  Methotrexate and folic reductase in human cancer.

Authors:  T C Hall; D Roberts; D H Kessel
Journal:  Eur J Cancer       Date:  1966-06       Impact factor: 9.162
  6 in total
  6 in total

Review 1.  Clinical pharmacokinetics of methotrexate.

Authors:  D D Shen; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

2.  Entero-hepatic cycling of methotrexate estimated by use of the D-isomer as a reference marker.

Authors:  J Hendel; H Brodthagen
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis.

Authors:  T S Tracy; K Krohn; D R Jones; J D Bradley; S D Hall; D C Brater
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Authors:  Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-02       Impact factor: 10.614

Review 5.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

6.  Methotrexate plasma decay kinetics: possible alteration in patients undergoing gut sterilization.

Authors:  P J Creaven; M H Cohen; L M Allen
Journal:  Br J Cancer       Date:  1976-11       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.